Tesamorelin is a full-length GHRH analog carrying a trans-3-hexenoic-acid modification that makes it bind GHRH receptors and drive strong GH pulses. It carries an FDA approval, marketed as Egrifta for HIV-associated lipodystrophy, and visceral-fat reduction is the effect the approval rests on.
- Rare in this category: an actual FDA approval, as Egrifta for HIV-associated lipodystrophy.FDA Egrifta approval
- A full-length GHRH analog with a trans-3-hexenoic-acid modification, engineered to bind GHRH receptors and produce strong nightly GH pulses.DailyMed: tesamorelin
- Visceral-fat reduction is described in the 8 to 12 week window.researchdosing
- FDA cleared a weekly-reconstitution formulation, Egrifta WR, in March 2025: same molecule, same indication.Egrifta WR approval, Mar 2025
- MASH/NAFLD outside HIV is a strong off-label research signal, but it is not an approved indication.PubMed: Tesamorelin